Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
905.38
-3.66 (-0.40%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
85
86
Next >
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
3 Magnificent Growth Stocks to Buy Right Now
February 19, 2024
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.
Via
The Motley Fool
3 Stocks Primed to Reach Trillion-Dollar Valuation
February 19, 2024
Explore the elite world of trillion-dollar stocks and uncover insights on the companies dominating the market with unparalleled valuations.
Via
InvestorPlace
Where Will Eli Lilly Be in 5 Years?
February 18, 2024
The stock will still be crushing the market in all likelihood.
Via
The Motley Fool
Warren Buffett's Empire Nears Trillion-dollar Club As Class A Shares Hit Above $600,000
February 17, 2024
This week, Berkshire Hathaway (NYSE: BRK-A) achieved a historic milestone as its Class A shares closed above $600,000 for the first time.
Via
Benzinga
3 Perfect Stocks to Buy This Valentine's Day
February 14, 2024
These stocks have sweet long-term prospects.
Via
The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,000 Today
February 13, 2024
Via
Benzinga
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?
February 12, 2024
The drugmaker continues to impress investors.
Via
The Motley Fool
Four Charts Every Trader Needs To See Today
February 17, 2024
As I’ve noted previously, the S&P 500 is quite extended above both its 10-week moving average (same as the 50-DMA) as well as the 40-week moving average (same as the 200-DMA).
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
SPDR ETF Report For Friday, February 16
February 17, 2024
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Friday, February 16.
Via
Talk Markets
Topics
ETFs
Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?
February 16, 2024
Eli Lilly's weight-loss and diabetes treatments Zepbound and Mounjaro should drive LLY stock much higher, said a Morgan Stanley analyst.
Via
Investor's Business Daily
My Top 3 Stock Candidates to Replace Tesla in the Magnificent 7
February 16, 2024
The Magnificent 7 stocks are mostly doing well in 2024. It would still be a good bet if not for Elon Musk’s company.
Via
InvestorPlace
What The Future Holds For Google's 'Other Bets'
February 16, 2024
Alphabet's far-ranging Other Bets tickle imaginations, but they've piled up huge losses. Google stock could benefit as discipline is imposed.
Via
Investor's Business Daily
Ray Dalio's Bridgewater Makes Waves: Q4 Unveils Strategic Shifts With New Investments, Sector Expansion In Tech
February 15, 2024
Bridgewater Associates, founded by Ray Dalio, made notable changes to its portfolio in Q4 2023. New bets, exits, increased stakes offer insights into its investment strategy.
Via
Benzinga
Meet the Next Trillion-Dollar Companies: Our Top 7 Picks
February 15, 2024
These future trillion-dollar stocks are on their way to mythic valuation, supported by strong underlying fundamentals and prospects.
Via
InvestorPlace
UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity
February 15, 2024
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients.
Via
Benzinga
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
February 15, 2024
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development.
Via
Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
February 14, 2024
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Via
InvestorPlace
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
February 14, 2024
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Eli Lilly Stock Wednesday?
February 14, 2024
Eli Lilly's shares surge 25% YTD to $700 billion enterprise value. Mounjaro and Zepbound drive growth with tirzepatide. BMO Capital projects $12.78 billion FY2024 tirzepatide revenues.
Via
Benzinga
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
February 14, 2024
It faces both clinical and competitive barriers, but they might not matter.
Via
The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
February 13, 2024
There's more for investors to get excited about in the biopharma world than just weight-loss drugs.
Via
The Motley Fool
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'
February 13, 2024
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry.
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
Eli Lilly's Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outlines What Lies Ahead
February 12, 2024
Track Eli Lilly's tripeptide success. Weekly updates on Mounjaro and Zepbound prescriptions in the GLP-1 category. Analyst predicts $12.78 billion in fiscal year 2024 tripeptide revenues.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
85
86
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.